Alkem Laboratories Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹67,335 Cr
- Book Value
- ₹1,156
- Stock P/E
- 27.6
- Dividend Yield
- 0.95%
- ROE
- 18.9%
- ROCE
- 21.2%
- PEG Ratio
- 2.94
- EV/EBITDA
- 18.8
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Alkem Laboratories share price today
Alkem Laboratories (NSE: ALKEM) owns the Indian pharmacy shelf where it matters most: anti-infectives, led by Clavam and a brand stable that ranks among the country’s most prescribed, plus gastro flagship Pan. Roughly two-thirds of revenue is domestic branded generics — the good kind of pharma, where brands compound and nobody in New Jersey sets your price.
The other third was the problem: US generics dragged margins for years. That drag is fading, and recent profit growth has run well ahead of the five-year averages as the mix shifts home. At 27.6× with a 21% ROCE, our universe tags it wait — cheaper than the MNC annuities, with the acute-therapy cyclicality to explain why.
The domestic engine, the US anchor
Alkem’s domestic franchise skews acute — antibiotics, cold-and-fever season, gastro — which means prescriptions swing with infection cycles rather than compounding like chronic therapy. The offset: brand strength so deep that doctors write “Clavam” as if it were the molecule. Chronic-share expansion (diabetes, cardiac) is the stated strategy, and the US business has been pruned toward profitability rather than volume.
Watch-items: seasonal acute demand (a weak infection season is a weak quarter), NLEM price-cap expansions, US pricing on the remaining exposure, and trade-generics competition in antibiotics.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹67,335 Cr |
| P/E (TTM) | 27.6 |
| EV/EBITDA | 18.8 |
| Operating margin | 20.4% |
| ROE / ROCE | 18.9% / 21.2% |
| Debt to equity | 0.15 |
| Sales CAGR (5y) | 10.7% |
| Profit CAGR (5y) | 9.4% |
| Promoter holding | 49.7% |
| EPS (TTM) | ₹202.9 |
Alkem Laboratories share price target 2026 to 2030
EPS base ₹202.9 (TTM). Bear: acute seasons disappoint and price caps widen — 6% growth, multiple at 18×. Base: domestic brands compound and the US stays repaired — 11% growth at 24×. Bull: chronic-share gains accelerate the mix — 15% growth at 30×.
| Year | Bear (18×, +6%) | Base (24×, +11%) | Bull (30×, +15%) |
|---|---|---|---|
| 2026 | ₹3,870 | ₹5,405 | ₹7,000 |
| 2027 | ₹4,105 | ₹6,000 | ₹8,050 |
| 2028 | ₹4,350 | ₹6,660 | ₹9,260 |
| 2029 | ₹4,610 | ₹7,390 | ₹10,645 |
| 2030 | ₹4,885 | ₹8,205 | ₹12,245 |
From ₹5,608, the base case is ≈ +46% over four and a half years plus a ~1% yield. The bear case is −13% — branded-domestic pharma rarely gets destroyed, it gets repriced. The range below waits for one of those repricings.
Reasons to own Alkem (at the right price)
- Anti-infectives leadership — among India’s most prescribed brand stables.
- Two-thirds domestic branded mix: pricing power without US FDA roulette.
- The US drag is fading — recent profit growth runs far ahead of the 5-year average.
- 27.6× is a discount to branded-domestic peers with similar franchises.
- Chronic-therapy expansion is upside optionality on an acute base.
The risks: acute portfolios are hostage to infection seasons, NLEM can cap a flagship’s price overnight, and ROE in the high teens trails the MNC pharma benchmarks.
Should you buy at the current price?
The live buy range below is for members — where seasonal softness turns into entry points.
FAQ
What is the Alkem Laboratories share price target for 2030? Base case ≈ ₹8,205 (24× on 11% compounded growth), bear ≈ ₹4,885, bull ≈ ₹12,245. Arithmetic above.
What are Alkem’s biggest brands? Clavam (antibiotic), Pan/Pan-D (gastro), Taxim (antibiotic) — several rank among India’s top-selling pharmaceutical brands by prescription.
Why did Alkem’s five-year profit CAGR look weak? US generic price erosion consumed what the domestic business earned. As the US mix shrank and pricing stabilised, consolidated growth re-accelerated — the TTM tells that story.
When are Alkem’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.